跳轉至內容
Merck
全部照片(1)

Key Documents

L0570000

左旋甲状腺素钠

European Pharmacopoeia (EP) Reference Standard

同義詞:

左旋甲状腺素钠 水合物, 3,3′,5,5′-四碘代-L-甲状腺原氨酸 单钠盐 水合物, O-(4-羟基-3,5-二碘代苯基)-3,5-二碘代-L-酪氨酸钠 水合物

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C15H10I4NNaO4 · xH2O
CAS號碼:
分子量::
798.85 (anhydrous basis)
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

levothyroxine

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

O.[Na+].N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C([O-])=O

InChI

1S/C15H11I4NO4.Na.H2O/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);;1H2/q;+1;/p-1/t12-;;/m0../s1

InChI 密鑰

ANMYAHDLKVNJJO-LTCKWSDVSA-M

基因資訊

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Levothyroxine sodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

STOT RE 1

標靶器官

Thyroid,Cardio-vascular system,Kidney

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Mazen Lee Hamad et al.
Pharmaceutical development and technology, 20(3), 314-319 (2013-12-04)
Levothyroxine sodium is an important medication used primarily for treating patients with hypothyroidism. Levothyroxine sodium tablets have been recalled many times since their 1955 introduction to the US market. These recalls resulted from the failure of lots to meet their

條款

HPLC Analysis of Levothyroxine and Liothyronine on Ascentis® Express ES-Cyano

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務